Bluejay Diagnostics, Inc. (BJDX)

NASDAQ: BJDX · IEX Real-Time Price · USD
0.818
-0.002 (-0.24%)
At close: Sep 28, 2022 4:00 PM
0.800
-0.018 (-2.20%)
After-hours: Sep 28, 2022 7:59 PM EDT
-0.24%
Market Cap 16.48M
Revenue (ttm) n/a
Net Income (ttm) -6.60M
Shares Out 20.15M
EPS (ttm) -0.42
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 39,990
Open 0.820
Previous Close 0.820
Day's Range 0.810 - 0.840
52-Week Range 0.810 - 6.250
Beta n/a
Analysts Buy
Price Target 8.16 (+897.6%)
Earnings Date Jul 27, 2022

About BJDX

Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosi... [Read more...]

Industry Medical Devices
IPO Date Nov 10, 2021
Employees 9
Stock Exchange NASDAQ
Ticker Symbol BJDX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for BJDX stock is "Buy." The 12-month stock price forecast is 8.16, which is an increase of 897.56% from the latest price.

Price Target
$8.16
(897.56% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Bluejay Diagnostics (NASDAQ:BJDX), BioSig Technologies (NASDAQ:BSGM) – Sharps Technology And 2 Other Stocks Under $2 ...

The Dow Jones closed higher by more than 400 points on Wednesday. Investors, meanwhile, focused on some notable insider trades.

Other symbols: BSGMSTSS
2 weeks ago - Benzinga

Bluejay Diagnostics, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference

ACTON, Mass., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-patie...

4 weeks ago - GlobeNewsWire

Bluejay Diagnostics, Inc. to Host Key Opinion Leader Event on IL-6 Testing in Critical Care Settings: The Emerging Us...

Webinar to be held Thursday, August 25th @ 11:00am EDT Webinar to be held Thursday, August 25th @ 11:00am EDT

1 month ago - GlobeNewsWire

Positive Clinical Results for Bluejay's Symphony IL-6 Test Presented at AACC 2022

Demonstrated 98% NPV 1 to Identify COVID-19 Patients at Risk for Severe Illness

2 months ago - GlobeNewsWire

Bluejay Diagnostics, Inc. Reports Second Quarter 2022 Financial Results

ACTON, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-pat...

2 months ago - GlobeNewsWire

Bluejay Completes Planned Clinical Studies for Symphony IL-6 Test

ACTON, Mass., July 06, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-patie...

2 months ago - GlobeNewsWire

Why Bluejay Diagnostics Shares Are Surging Higher Today

Shares of small-cap penny stock Bluejay Diagnostics, Inc. (NASDAQ: BJDX) are trading higher after the company announced that the FDA has agreed to consider its plan to pursue a De Novo submission for th...

3 months ago - Benzinga

Bluejay Diagnostics, Inc. Reports First Quarter 2022 Financial Results

ACTON, Mass., April 20, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a pre-revenue medical diagnostics company focused on developing cost-effective, rapi...

5 months ago - GlobeNewsWire

Bluejay Diagnostics Appoints Edwin Rule as Vice President, Regulatory, Quality and Compliance

ACTON, Mass., March 28, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”) a late-stage, pre-revenue diagnostics company focused on developing cost-effective, r...

6 months ago - GlobeNewsWire

Bluejay Diagnostics Appoints Kenneth Fisher as Chief Financial Officer

ACTON, Mass., March 24, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a late-stage, pre-revenue diagnostics company focused on developing cost-effective, ...

6 months ago - GlobeNewsWire

Bluejay Diagnostics, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Testing program underway for lead product candidate, the Symphony IL-6 Test, in support of an FDA Marketing Application, planned for Q3 2022

6 months ago - GlobeNewsWire

Bluejay Diagnostics, Inc. Announces its Pre-Submission Filing Package for the Symphony IL-6 Test is with the FDA

ACTON, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”) a late-stage, pre-revenue diagnostics company focused on developing cost-effective, ra...

7 months ago - GlobeNewsWire

Bluejay Diagnostics, Inc. Completes 90 Subjects in Multicenter Clinical Study Addressing Rapid IL-6 Test for COVID-19...

This Study performs unique rapid on-site measurement using patient whole blood and positions Company to move forward with multiple initiatives This Study performs unique rapid on-site measurement using ...

8 months ago - GlobeNewsWire

10 Low-Float Penny Stocks for Steel-Gutted Investors

If you're willing to absorb massive risk for the chance of significant upside, these low-float penny stocks could fit the bill. The post 10 Low-Float Penny Stocks for Steel-Gutted Investors appeared fir...

8 months ago - InvestorPlace

Bluejay Diagnostics, Inc. Appoints Mark Feinberg, M.D. as Chief Medical Advisor

ACTON, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”) a late-stage, pre-revenue diagnostics/medical device company focused on developing cost-effective, ra...

8 months ago - GlobeNewsWire

Bluejay Diagnostics, Inc. Reports Third Quarter 2021 Financial Results

IL-6 test for sepsis triage on Track for January 2022 FDA Pre-Submission Filing

9 months ago - GlobeNewsWire

Bluejay Diagnostics, Inc. Announces Pricing of Upsized $21.6 Million Initial Public Offering

ACTON, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”) a late-stage, pre-revenue diagnostics/medical device company focused on developing cost-effective, ra...

10 months ago - GlobeNewsWire